Proactive Investors - Run By Investors For Investors

Hemispherx Biopharma updates on current trials, gears up to begin 5 more

Hemispherx Biopharma Inc (NYSE American:HEB) CEO Tom Equels updates Proactive Investors on its US trials with cancer drug candidate Ampligen, and says the biopharma is initiating five additional Ampligen trials this year.

Equels says he'd like to source the $8-10 million needed to begin these new studies from government grants and industry support.

 
View full HEB profile View Profile

Hemispherx Biopharma Inc Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use